Description
AP-26113 (brigatinib) is a pan inhibitor of ALK. It is a leading candidate for the treatment of ALK+ non-small-cell lung cancer, especially those with major resistance mechanisms. AP-26113 exhibits efficacy against models of ALK+ anaplastic large cell lymphoma in cases where crizotinib, an approved drug for late-stage and metastatic lung cancers, fails due to developed drug resistance.